Vancouver, B.C. / TheNewswire / May 17, 2017 – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of David Greenway as a Director of the Company.

 

Mr. Greenway has two decades of experience in managing, financing, and developing growth strategies for various TSX Venture Exchange and CSE listed companies. His key expertise lies in the management and development of junior public resource companies, especially in the mining, and oil and gas sector. He has held directorships, senior management and business development positions including his role as the CEO of Stamper Oil & Gas Corp, Chief Consolidated Gold Mines, SNS Silver Corp and his board position in Mountain View Conservation Centre.

 

Lui Franciosi commented: “We are very pleased to welcome David to Veritas’ Board of Directors. His experience and relationships in capital markets and with financing companies will serve well and be a significant asset to the Company as we continue to execute our business plan and advance its business objectives.”

 

Veritas also wishes to announce the resignation of Director Matthew Hamilton. The Board and Management would like to sincerely thank Matthew for his contribution to the development of Veritas and wish him well in his future endeavors.

  

About Veritas Pharma Inc.

 

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

  

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

 

For more information, please visit our website: www.veritaspharmainc.com

 

On behalf of the Board of Directors; Veritas Pharma Inc.

 

"Dr. Lui Franciosi"

Dr. Lui Franciosi

Chief Executive Officer

 

Further information about the Company is available on our website at www.veritaspharmainc.com  or under our profile on SEDAR at www.sedar.com  and on the CSE website at www.thecse.com

 

Investor and Public Relations Contact

Veritas Pharma Inc.

Sam Eskandari

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

 

The CSE has not reviewed, nor approved or disapproved the content of this press release.